Skip to content

Letrozole High Dose (10 mg) Compared to Letrozole Low Dose( 5 mg) for Ovarian Stimulation in Infertile Women With Polycystic Ovary Syndrome

Letrozole High Dose (10 mg) Compared to Letrozole Low Dose( 5 mg) for Ovarian Stimulation in Infertile Women With Polycystic Ovary Syndrome

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07759518
Acronym
PCOS OID
Enrollment
86
Registered
2026-08-12
Start date
2025-02-01
Completion date
2026-02-01
Last updated
2026-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PCOS

Brief summary

The goal of this clinical trial is to learn if drug letrozole 10mg for 5 days works better than letrozole 5mg for 5 days for ovarian stimulation in infertile women with PCOS. It will also learn about the safety of drug letrozole . The main questions it aims to answer are: What medical problems do participants have when taking drug letrozole? Researchers will compare drug letrozole 10mg for 5 days works better than letrozole 5 mg for 5 days for ovarian stimulation in infertile women with PCOS Participants will: The experimental arm (p1) will be treated with letrozole 10 mg for 5 days. The comparator arm (p2) will receive letrozole 5 mg for 5 days for ovulation induction for consecutive 3 months Treatment will start from the 2nd day of menstruation cycle or withdrawal bleeding after the baseline visit and investigations. Ovarian response will be assessed by trans-vaginal monitoring of follicle growth around day 10 of menstrual cycle

Detailed description

Atotal number of 86 eligible PCOS women will be randomized to either letrozole 10 mg for 5 days or letrozole 5 mg for 5 days for ovulation induction. The experimental arm (p1) will be treated with letrozole 10 mg for 5 days. The comparator arm (p2) will receive letrozole 5 mg for 5 days (Tab letrol 2.5mg -Renata Pharmaceutical. Treatment will start from the 2nd day of menstruation cycle or withdrawal bleeding after the baseline visit and investigations. Ovarian response will be assessed by trans-vaginal monitoring of follicle growth around day 10 of menstrual cycle.The presence of preovulatory follicle, multifollicular development, the number of developing follicles, size of largest follicle and endometrial thickness with pattern will be assessed. The woman will then be advised to test for LH surge by urinary LH kit daily until positive and when positive will have intercourse for two days. She will have serum progesterone estimation after 7 days. She will repeat same dose of ovulation induction if she has menstruation and if there are no symptoms of side effect regarding letrozole intake or will do pregnancy test if she misses period. If missed period occurs further visit will be required for serum β-hCG estimation for confirmation of pregnancy. If pregnancy test is positive she will do an USG for fetal cardiac motion around 7-8 weeks.If B-hCG negative I will give the woman Tab. Norethisterone (5mg) (Tab. Normens 5mg - Renata pharmaceuticals) for (7-10) days for withdrawal bleeding. After withdrawal bleeding I will give her previous dose letrozole. In that situation she will define as a case of anovulation. If cyst appears I will do a Transvaginal sonography of that woman in D2 of the cycle to observe the cyst. If cyst persist, I will hold stimulation in that cycle. If cyst disappear I will give stimulation. All subject will receive drugs (Tab. Letrol 2.5mg, Tab. Normens 5mg) from me. I will ensure their proper intake by cell phone and during their visit they will show their blank strip of drug for confirmation. The cumulative data will be subjected to analysis. by Statistical Package for Social Sciences version 27 for Windows (SPSS Inc., Chicago, Illinois, USA).

Interventions

DRUGTab.Letrozole 10 mg for 5 days

Tablet letrozole 10mg for 5 days from day 2-3 of enstruation/withdrawal bleeding (10mg in divided dose-5mg in morning \& 5mg at bed time for 5 days) for three months

DRUGTab.Letrozole 5mg for 5 days

Tab letrozole 5mg for 5 days from day 2-3 ofenstruation/withdrawal bleeding (5mg at bed time for 5 days) for three months.

Sponsors

Mst.Sumyara Khatun
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

1. Age: 18-35 years old 2. BMI : 18-30 kg/m2 3. Diagnosed cases of PCOS patients according to Rotterdam criteria. 4. Corrected hypothyroidism and hyperprolactinemia

Exclusion criteria

1. Women with other infertility factors (endometriosis, tubal and uterine causes of infertility) 2. Male factor infertility 3. Impaired hepatic or renal function 4. History of hypersensitivity to letrozole \- \-

Design outcomes

Primary

MeasureTime frameDescription
Presence of preovulatory follicle12 weeksPreovulatory follicle:A follicle14 mm or more
Multifollicular development12 weeksMultifollicular development: Presence of more than one preovulatory follicle

Secondary

MeasureTime frameDescription
Ovulation Rate3 monthsOvulation:Ovulation will be diagnosed by presence of any one of following • Detecting LH surge in ovulation predictor kit • Day 21 progesterone level ≥ 3 ng/dl • An appropriately timed menses in previously oligomenorrheic patient • A positive pregnancy test
Pregnancy rate3 monthsPregnancy: Pregnancy will be determined after missed period by serum β-hCG estimation. Serum β-hCG\> 5 mIU/mL is diagnosed as pregnancy \[ Atellica integrated clinical chemistry and immunoassay analyzer\] followed by the presence of fetal cardiac motion on ultrasound around 7-8wk
Number of developing follicles3 monthsDeveloping follicle:Follicles with mean diameter between 10-13 mm
Days to LH surge3 monthsDays to LH surge: The number of days from the first dose of letrozole to LH surge determined by ovulation predictor kit.

Countries

Bangladesh

Contacts

STUDY_DIRECTORShakeela Ishrat

Bangladesh Medical University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 13, 2026